69 related articles for article (PubMed ID: 3495618)
21. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z
Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
[TBL] [Abstract][Full Text] [Related]
22. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
Ortaldo JR; Frey J; Takeshita T; Sugamura K
Eur Cytokine Netw; 1990; 1(1):27-34. PubMed ID: 2151685
[TBL] [Abstract][Full Text] [Related]
23. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
24. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
25. Precursor phenotype of lymphokine-activated killer cells in the mouse.
Salup RR; Mathieson BJ; Wiltrout RH
J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
Fuchshuber PR; Lotzová E; Pollock RE
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
[TBL] [Abstract][Full Text] [Related]
27. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
Mueller EA; Anderer FA
Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
[TBL] [Abstract][Full Text] [Related]
28. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
29. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
Brooks B; Rees RC
Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652
[TBL] [Abstract][Full Text] [Related]
30. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
31. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
Kawakami Y; Custer MC; Rosenberg SA; Lotze MT
J Immunol; 1989 May; 142(10):3452-61. PubMed ID: 2654291
[TBL] [Abstract][Full Text] [Related]
32. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
Atzpodien J; Gulati SC
Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
[TBL] [Abstract][Full Text] [Related]
33. Effect of interleukin-15 and Flt3-ligand on natural killer cell expansion and activation: umbilical cord vs. adult peripheral blood mononuclear cells.
Lin SJ; Yang MH; Chao HC; Kuo ML; Huang JL
Pediatr Allergy Immunol; 2000 Aug; 11(3):168-74. PubMed ID: 10981526
[TBL] [Abstract][Full Text] [Related]
34. Generation of lymphokine-activated killer cell activity from human thymocytes.
Ramsdell FJ; Golub SH
J Immunol; 1987 Sep; 139(5):1446-53. PubMed ID: 2442246
[TBL] [Abstract][Full Text] [Related]
35. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
[TBL] [Abstract][Full Text] [Related]
36. [Immunoglobulin production of neonate--T lymphocyte subset and production of cytokine].
Saito M; Saito S; Moriyama I; Ibaragi T; Ichijo M
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Nov; 39(11):1973-9. PubMed ID: 3323359
[TBL] [Abstract][Full Text] [Related]
37. Natural killer cell activity in very low birth weight infants.
McDonald T; Sneed J; Valenski WR; Dockter M; Cooke R; Herrod HG
Pediatr Res; 1992 Apr; 31(4 Pt 1):376-80. PubMed ID: 1570204
[TBL] [Abstract][Full Text] [Related]
38. [Studies on the influence of interleukin 2 (IL-2) on antitumor effector mechanisms in patients with cervical cancer].
Yamamoto K
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Dec; 38(12):2251-8. PubMed ID: 3492578
[TBL] [Abstract][Full Text] [Related]
39. [Phenotypic expression and functional manifestation of fetal and maternal natural killer (NK) cells].
Miyakawa S; Tsunoda H; Iwasaki H; Kaneko M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):543-9. PubMed ID: 2754285
[TBL] [Abstract][Full Text] [Related]
40. NK cell increase in neonates from the preterm to the full-term period of gestation.
Pérez A; Gurbindo MD; Resino S; Aguarón A; Muñoz-Fernández MA
Neonatology; 2007; 92(3):158-63. PubMed ID: 17429221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
